Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | C3AR1 | Q16581 | 5/20 | 0.46 |
| ▸ | FNTA | P49354 | 1/20 | 0.46 |
| ▸ | FNTB | P49356 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7598387 | 0.82 | CHRM1 (0.52) | CHRM1CYP3A4FNTAFNTB | |
| SCHEMBL7594737 | 0.81 | GFER (0.54) | CHRM1CYP1A2CYP2C19 | |
| SCHEMBL4778905 | 0.79 | CHRM1 (0.60) | CHRM1NAMPTCYP3A4FNTAFNTB | |
| SCHEMBL3458346 | 0.77 | DRD2 (0.54) | — | |
| SCHEMBL2495367 | 0.77 | CYP1A2 (0.58) | NAMPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8086170 | 0.77 | CYP1A2 (0.58) | NAMPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL83847 | 0.76 | LMNA (0.51) | CYP1A2CYP3A4CYP2C9CYP2C19C3AR1 | |
| SCHEMBL7595694 | 0.75 | AVPR1B (0.48) | CHRM1NAMPTPOLB | |
| SCHEMBL31350736 | 0.74 | FNTA (0.76) | CHRM1CYP3A4FNTAFNTB | |
| SCHEMBL83930 | 0.74 | LMNA (0.49) | CYP1A2CYP3A4CYP2C9CYP2C19C3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020119979-A1 | Acyclic compounds and methods for treating multidrug resistance | PROCTER & GAMBLE COMPANY, THE | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119979-A1 | Acyclic compounds and methods for treating multidrug resistance | ABCC1, ABCB1, ABCB11 | CHRM1 3787/4885NAMPT 659/4885CYP1A2 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.